Clinical Trials in San Diego

Showing 11521-11540 of 14,679 trials

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

NCT00280956

The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.

Crohn's Disease

Biogen2,000 participantsStarted Jul 2002

San Diego, California, United States

COMPLETEDPhase 3< 1 mile

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

NCT00032799

The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.

Crohn's Disease

Biogen905 participantsStarted Dec 2001

San Diego, California, United States

UNKNOWNPhase 2< 1 mile

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

NCT02395549

This study is designed to investigate the efficacy, safety and tolerability of MTC896 Gel in subjects with acne. In this study, MTC896 Gel will be applied at 3 concentrations, twice daily (bid) for 12 weeks and compared against a vehicle control.

Acne Vulgaris

Mimetica Pty Limited364 participantsStarted Apr 2015

Sacramento, California, United States • San Diego, California, United States • San Diego, California, United States +17 more locations

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

Find Trials by Condition in San Diego

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Ocriplasmin Research to Better Inform Treatment (ORBIT)

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Expanded Access to ANG1005 for Individual Patients

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

Pilot Study to Evaluate The Effectiveness And Safety Of Axiom Worldwide Drx9000™ Spinal Decompression System

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)